JUN 3 0 2006

2183 BFF #W

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313 on

June 27, 2004

Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE STATEMENT Examining Group 2183 Patent Application Docket No. ARS-106 Serial No. 10/517,726

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit

2183

Applicants

Amanda Proudfoot, Marie Kosco-Vilbois

Serial No.

10/517,726

Filed

December 10, 2004

Conf. No.

6045

For

Novel Antagonists of CXCR3-Binding CXC Chemokines

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

The patent application referred to above was filed in the U.S. Patent Office as a national application under 35 USC §371. Applicants have been notified that a copy of the International Search Report has been made available in the national stage file as indicated on the Notice of Acceptance of the Application Under 35 USC 371 (Form PCT/DO/EO/903). The Notice does not indicate whether copies of the references cited in the International Search Report were received by the Patent Office. Therefore, copies of the references cited in the International Search Report are enclosed for the Examiner's convenience. However, Applicants have not submitted copies of the U.S. patents and U.S. published Patent Application cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

In accordance with 37 CFR §1.56, Applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:

P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of cited references.

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number	10/517,726	
					Filing Date	December 10, 2004
					First Named Inventor	Amanda Proudfoot
				•	Art Unit	2183
				Examiner Name		
Sheet	1	of	2		Attorney Docket Number	ARS-106

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	U1	US-5,739,103	04-14-1998	Rollins <i>et al.</i>	All	
	U2	US-2002-018776 A1	02-14-2002	Hancock	All	
	U3	US-6,140,064	10-31-2000	Loetscher <i>et al.</i>	All	
	U4	US-5,977,334	11-02-1999	Ransohoff et al.	All	
	U5	US-5,656,724	08-12-1997	Daly <i>et al</i> .	All	
	U6	US-5,969,093	10-19-1999	Jacobs <i>et al.</i>	All	
	U7	US-				
	U8	US-				
	U9	US-				

FOREIGN PATENT DOCUMENTS						
Examiner . Cite . No. 1		Foreign Patent Document		Publication Date Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
			MM-DD-YYYY			
	INO.	Country Code 3 - Number 4 - Kind Code5 (if known)				T ⁶
	F1	WO 02/43758 A2	06-06-2002	Schering Corp.	All	
				Gryphon		
	F2	WO 02/04015 A1 (CD-ROM)	01-17-2002	Therapeutics, Inc.	All	l
	F3					
	F4					
	F5					
	F6					
	F7			. ,		

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (MPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Complete if Known Substitute for form 1449B/PTO **Application Number** 10/517,726 INFORMATION DISCLOSURE Filing Date December 10, 2004 STATEMENT BY APPLICANT **First Named Inventor** Amanda Proudfoot **Group Art Unit** 2183 (use as many sheets as necessary) **Examiner Name ARS-106 Attorney Docket Number** Sheet of

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹						
	R1	LOERTSCHER, P. et al. "The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3" <i>The Journal of Biological Chemistry</i> , February 2, 2001, pp. 2986-2991, Vol. 276, No. 5.					
	R2						
	R3						
	R4						
	R5						
	R6						
	R7						
	R8						
	R9						
	R10						
	R11						
	R12						

Examiner	•	Date	
Signature	·	Considered	

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.